Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2009 2
2010 4
2011 2
2012 1
2013 1
2014 7
2015 7
2016 5
2017 5
2018 4
2019 6
2020 6
2021 7
2022 7
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Results by year

Filters applied: . Clear all
Page 1
REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas.
Picca A, Touat M, Belin L, Gourmelon C, Harlay V, Cuzzubbo S, Cohen-Jonathan Moyal E, Bronnimann C, Di Stefano AL, Laurent I, Lerond J, Carpentier C, Bielle F, Ducray F, Dehais C; POLA Network. Picca A, et al. Among authors: dehais c. Eur J Cancer. 2024 May;202:114034. doi: 10.1016/j.ejca.2024.114034. Epub 2024 Mar 22. Eur J Cancer. 2024. PMID: 38537315 Clinical Trial.
A threshold for mitotic activity and post-surgical residual volume defines distinct prognostic groups for astrocytoma IDH-mutant.
Tran S, Thomas A, Aliouat I, Karachi C, Lozano F, Mokhtari K, Dehais C, Feuvret L, Carpentier C, Giry M, Doukani A, Lerond J, Marie Y, Sanson M, Idbaih A, Carpentier A, Hoang-Xuan K, Touat M, Capelle L, Bielle F. Tran S, et al. Among authors: dehais c. Neuropathol Appl Neurobiol. 2023 Aug;49(4):e12928. doi: 10.1111/nan.12928. Neuropathol Appl Neurobiol. 2023. PMID: 37503540
A Multigene Signature Associated with Progression-Free Survival after Treatment for IDH Mutant and 1p/19q Codeleted Oligodendrogliomas.
Gilhodes J, Meola A, Cabarrou B, Peyraga G, Dehais C, Figarella-Branger D, Ducray F, Maurage CA, Loussouarn D, Uro-Coste E, Cohen-Jonathan Moyal E, Pola Network. Gilhodes J, et al. Among authors: dehais c. Cancers (Basel). 2023 Jun 6;15(12):3067. doi: 10.3390/cancers15123067. Cancers (Basel). 2023. PMID: 37370678 Free PMC article.
Mismatch Repair Deficiency and Lynch Syndrome Among Adult Patients With Glioma.
Benusiglio PR, Elder F, Touat M, Perrier A, Sanson M, Colas C, Guerrini-Rousseau L, Tran DT, Trabelsi N, Carpentier C, Marie Y, Adam C, Bernier M, Cazals-Hatem D, Mokhtari K, Tran S, Mathon B, Capelle L, Dhooge M, Idbaih A, Alentorn A, Houillier C, Dehais C, Hoang-Xuan K, Cuzzubbo S, Carpentier A, Duval A, Coulet F, Bielle F. Benusiglio PR, et al. Among authors: dehais c. JCO Precis Oncol. 2023 May;7:e2200525. doi: 10.1200/PO.22.00525. JCO Precis Oncol. 2023. PMID: 37262394
T2-Fluid-attenuated inversion recovery (FLAIR) pseudoprogression in patients with anaplastic oligodendrogliomas treated with procarbazine, lomustine and vincristine (PCV) chemotherapy alone.
Esparragosa Vazquez I, Ndiaye M, Di Stefano AL, Younan N, Larrieu-Ciron D, Seyve A, Picart T, Meyronet D, Boutet C, Vassal F, Carpentier C, Figarella-Branger D, Dehais C, Forest F, Rivoirard R, Ducray F; POLA network. Esparragosa Vazquez I, et al. Among authors: dehais c. Eur J Neurol. 2023 Sep;30(9):2879-2883. doi: 10.1111/ene.15873. Epub 2023 May 31. Eur J Neurol. 2023. PMID: 37204066
Characteristics, Patterns of Care and Predictive Geriatric Factors in Elderly Patients Treated for High-Grade IDH-Mutant Gliomas: A French POLA Network Study.
Montégut C, Guillamo JS, Ducray F, Dehais C, Cohen-Jonathan Moyal E, Desenclos C, Petit A, Seizeur R, Bekaert L, Gaultier C, Motuo Fotso MJ, Blonski M, Frenel JS, Vauléon E, Langlois O, Noel G, Carpentier AF, Di Stefano AL, Bronnimann C, Figarella-Branger D, Chinot O, Tabouret E. Montégut C, et al. Among authors: dehais c. Cancers (Basel). 2022 Nov 9;14(22):5509. doi: 10.3390/cancers14225509. Cancers (Basel). 2022. PMID: 36428602 Free PMC article.
In Vivo 2-Hydroxyglutarate Monitoring With Edited MR Spectroscopy for the Follow-up of IDH-Mutant Diffuse Gliomas: The IDASPE Prospective Study.
Di Stefano AL, Nichelli L, Berzero G, Valabregue R, Touat M, Capelle L, Pontoizeau C, Bielle F, Lerond J, Giry M, Villa C, Baussart B, Dehais C, Galanaud D, Baldini C, Savatovsky J, Dhermain F, Deelchand DK, Ottolenghi C, Lehéricy S, Marjańska M, Branzoli F, Sanson M. Di Stefano AL, et al. Among authors: dehais c. Neurology. 2023 Jan 3;100(1):e94-e106. doi: 10.1212/WNL.0000000000201137. Epub 2022 Sep 30. Neurology. 2023. PMID: 36180241 Free PMC article.
Incidence and characteristics of pseudoprogression in IDH-mutant high-grade gliomas: A POLA network study.
Seyve A, Dehais C, Chinot O, Djelad A, Cohen-Moyal E, Bronnimann C, Gourmelon C, Emery E, Colin P, Boone M, Vauléon E, Langlois O, di Stefano AL, Seizeur R, Ghiringhelli F, D'Hombres A, Feuvret L, Guyotat J, Capelle L, Carpentier C, Garnier L, Honnorat J, Meyronet D, Mokhtari K, Figarella-Branger D, Ducray F. Seyve A, et al. Among authors: dehais c. Neuro Oncol. 2023 Mar 14;25(3):495-507. doi: 10.1093/neuonc/noac194. Neuro Oncol. 2023. PMID: 35953421 Free PMC article.
63 results